

## AMENDMENT

### LISTING OF CLAIMS

The following listing of claims replaces all prior listing and versions thereof:

1. (Canceled)
2. (Currently amended) A method for immunization and treatment of a human against atherosclerosis or an atherosclerotic related disease, the method comprising the step of administering to the human a pharmaceutical composition comprising an antibody preparation, ~~for example a monoclonal antibody,~~ with specificity to a phosphorylcholine conjugate.
3. (Currently amended) ~~The use of claim 1 or~~ method of claim 2 wherein ~~the medicament is for administration by injection or wherein the composition is administered by injection.~~
4. (Currently amended) ~~The use or method of any one of the preceding claims~~claim 2, wherein the phosphorylcholine is linked to a carrier via a spacer.
5. (Currently amended) ~~The use or method according to~~claim 2~~claim 4,~~ wherein the phosphorylcholine conjugate is linked to a protein carrier, optionally via a spacer is a protein.
6. (Currently amended) ~~The use or method according to~~ claim 5, wherein the protein is KLH (keyhole limpet hemocyanin) or human serum albumin (HSA).
7. (Currently amended) ~~The use or method according to~~ claim 4,<sub>1</sub> wherein the phosphorylcholine conjugate comprises phosphorylcholine linked to a latex bead, optionally via a spacer~~carrier is latex beads.~~
8. (Currently amended) A method of prophylactic or therapeutic treatment of a human being suffering from atherosclerosis or facing the risk of developing

ischemic cardiovascular disease, whereby a therapeutically effective amount of an antibody preparation, ~~for example a monoclonal antibody~~, with specificity to a phosphorylcholine conjugate is administered.

9. ~~(Currently amended) Use of a phosphorylcholine conjugate in a~~ method for assessing a human patient's risk of developing or progression of cardiovascular disease ~~in which the~~comprising assessing said patient's levels of antibodies reactive with the phosphorylcholine conjugate ~~are assessed~~, wherein low levels of antibody reactive with the phosphorylcholine conjugate are predictive of the occurrence of cardiovascular disease in a healthy human patient.
10. (Currently amended) The ~~use~~method of claim 9, wherein the cardiovascular disease is ischemic cardiovascular disease.
11. (Currently amended) The ~~use~~method of claim 9, wherein the cardiovascular disease is atherosclerosis.
12. (Currently amended) The ~~use~~method of ~~any one of claims 9 to 14~~claim 9, wherein the patient's levels of IgM antibodies reactive with the phosphorylcholine conjugate are assessed.
13. (Currently amended) The ~~use~~method of ~~any one of claims 9 to 14~~claim 9, wherein the patient's levels of IgG antibodies reactive with the phosphorylcholine conjugate are assessed.
14. (Currently amended) ~~Use according to any one of claims 9 to 13~~The method of claim 9, wherein phosphorylcholine is linked to a carrier via a spacer.
15. (Currently amended) ~~Use according to claim 14~~The method of claim 9, wherein the ~~phosphorylcholine conjugate comprises phosphorylcholine linked to a protein carrier, optionally via a spacer~~carrier is a protein.
16. (Currently amended) ~~Use according to claim 15~~The method of claim 15, wherein the protein is KLH (keyhole limpet hemocyanin) or human serum albumin (HSA).

17. (Currently amended) ~~Use according to claim 14~~The method of claim 9, wherein the phosphorylcholine conjugate comprises phosphorylcholine linked to a latex bead, optionally via a spacer carrier is latex beads.
18. (Currently amended) ~~Use according to any one of claims 9 to 17~~The method of claim 9, wherein the assay is an immunoassay.
19. (New) The method of claim 2, wherein said antibody preparation is a monoclonal antibody preparation.
20. (New) The method of claim 8, wherein said antibody preparation is a monoclonal antibody preparation.